Navigation Links
Mutation connected to Osteoporosis

Researchers report they have identified a genetic defect that causes a rare bone disease in which the body makes too much bone, a finding that may lead to treatments for osteoporosis. According to Dr. Michael Levyn, director of the bone and mineral center at Hopkins University, the new finding will help bone researchers understand why the body loses the ability to make new bone cells as people age.//

Later, Levine explained the researchers studied DNA from 15 people who have a condition called progressive osseous heteroplasia or POH. People who have POH form extraskeletal bone, essentially small rice-like bone fragments that grow in various organs in the body. He said DNA from the patients revealed 13 of the 18 shared a GNAS1 mutation -- guanine nucleotide binding protein alpha stimulating activity polypeptide. GNAS1 controls a protein that plays a critical role in way cells function. In the case of POH, the GNAS1 mutation results in a mistaken signal to non-skeletal cells, which results in the creation of bone by the misinformed cells.

Levyn, who also worked with researchers from the University of Pennsylvania School of Medicine, the Royal Children's Hospital in Melbourne, Australia, and the Washington University School of Medicine in St. Louis, said the finding may lead to development of a genetic treatment for POH. But he said the real significance of the research might be the light it sheds on the genetic basis for bone formation. Although about one in 100,000 people have POH, many millions of people will develop osteoporosis, which affects most elderly women and many elderly men.

Up until age 30 healthy people have the ability to grow new bone but after that time the bone building cells, called osteoblasts die off and with those cells goes the ability to make bone. As the mineral content of bone decreases, the bones become fragile and easily break, which leads to the disability associated with osteoporosis.

Currently, osteop orosis treatment is aimed at replacing calcium in bones but there is no approved treatment aimed at growing new bones. Since the GSNA1 mutation is instructing cells to differentiate not into muscle, fat or skin but rather into bone it may provide a model to help researchers understand how they can manipulate cells in people with osteoporosis to grow bone.

Dr. Michael J. Econs, a bone researcher at the University of Indiana, Indianapolis, said Levine's team might be on the right track. "In a very general sense, the more we know about genes that are important in bone formation or born resorbtion or mineralization, the more likely we are to be able to design therapies for various metabolic bone diseases, including osteoporosis." Econs was not involved in the research. Dr. Craig Langman of Northwestern University Medical School and the kidney and mineral metabolism center at Children's Memorial Hospital, Chicago, agreed the new research might pave the way for development of "designer drugs that really target this mutation."

But Langman cautioned it is premature to suggest this new finding will quickly lead to development of osteoporosis treatments. He predicted that it would have more value in finding ways to "treat this particular genetic disease." The research was funded by a grant from the National Institutes of Health and the Johns Hopkins University School of Medicine's General Clinical Research Center.


'"/>




Related medicine news :

1. Stem Cells Have Few Mutations
2. Gene Mutation Causes Ovarian Failure
3. Mutations in NOTCH1 cause an early developmental defect in the aortic valve
4. A Word Of Caution: Routine Screening For Breast Cancer Mutation Not Advisdable
5. Coffee Reduces Risk of Breast Cancer in BRCA1 Mutation Carriers
6. CCR5 Mutation Confers Immunity Against HIV But Not Against West Nile Virus Illness
7. Wound Healing Accelerated By Mutation In Deafness Gene
8. No Mutation Of Bird Flu Virus: WHO
9. Gene Mutation May Influence Age at Onset of Parkinsons Disease
10. Menin Gene Mutation made Insulin Secreting Cells to Proliferate
11. Developing Countries Undertake Cataloguing of Human Mutations
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to improve ... engagement.” The patient is doing more than filling out a survey; in many cases ... an increasing emphasis in health care and research on the importance of active engagement ...
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
Breaking Medicine Technology: